Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free NDRA Stock Alerts

ENDRA Life Sciences (NDRA) Competitors

ENDRA Life Sciences logo
$4.47 0.00 (0.00%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$4.39 -0.08 (-1.79%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

NDRA vs. LFWD, TMDIF, NMTC, IRIX, and ZJYL

Should you buy ENDRA Life Sciences stock or one of its competitors? ENDRA Life Sciences's main competitors and comparable companies include Lifeward (LFWD), Titan Medical (TMDIF), NeuroOne Medical Technologies (NMTC), IRIDEX (IRIX), and Jin Medical International (ZJYL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does ENDRA Life Sciences compare to Lifeward?

ENDRA Life Sciences (NASDAQ:NDRA) and Lifeward (NASDAQ:LFWD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

In the previous week, Lifeward had 4 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 6 mentions for Lifeward and 2 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 1.87 beat Lifeward's score of 0.62 indicating that ENDRA Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
ENDRA Life Sciences Very Positive
Lifeward Positive

ENDRA Life Sciences has higher earnings, but lower revenue than Lifeward. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ENDRA Life SciencesN/AN/A-$7.03M-$8.15N/A
Lifeward$22.03M0.96-$19.91M-$19.66N/A

1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 26.8% of Lifeward shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 1.5% of Lifeward shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ENDRA Life Sciences presently has a consensus target price of $25.00, suggesting a potential upside of 459.28%. Lifeward has a consensus target price of $10.00, suggesting a potential upside of 34.23%. Given ENDRA Life Sciences' higher possible upside, equities analysts clearly believe ENDRA Life Sciences is more favorable than Lifeward.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Lifeward
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

ENDRA Life Sciences has a net margin of 0.00% compared to Lifeward's net margin of -123.66%. Lifeward's return on equity of -243.14% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ENDRA Life SciencesN/A -433.64% -204.58%
Lifeward -123.66%-243.14%-97.39%

ENDRA Life Sciences has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market. Comparatively, Lifeward has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Summary

Lifeward beats ENDRA Life Sciences on 7 of the 13 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Titan Medical?

ENDRA Life Sciences (NASDAQ:NDRA) and Titan Medical (NASDAQ:TMDIF) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

In the previous week, ENDRA Life Sciences had 2 more articles in the media than Titan Medical. MarketBeat recorded 2 mentions for ENDRA Life Sciences and 0 mentions for Titan Medical. ENDRA Life Sciences' average media sentiment score of 1.87 beat Titan Medical's score of 0.00 indicating that ENDRA Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
ENDRA Life Sciences Very Positive
Titan Medical Neutral

ENDRA Life Sciences currently has a consensus price target of $25.00, suggesting a potential upside of 459.28%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe ENDRA Life Sciences is more favorable than Titan Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Titan Medical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 0.0% of Titan Medical shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 0.0% of Titan Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ENDRA Life Sciences has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Titan Medical's return on equity of -82.31% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ENDRA Life SciencesN/A -433.64% -204.58%
Titan Medical N/A -82.31%-51.47%

Titan Medical has higher revenue and earnings than ENDRA Life Sciences. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ENDRA Life SciencesN/AN/A-$7.03M-$8.15N/A
Titan Medical$17.63M0.95$6.95M$0.052.93

Summary

ENDRA Life Sciences and Titan Medical tied by winning 7 of the 14 factors compared between the two stocks.

How does ENDRA Life Sciences compare to NeuroOne Medical Technologies?

NeuroOne Medical Technologies (NASDAQ:NMTC) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

NeuroOne Medical Technologies has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market.

In the previous week, NeuroOne Medical Technologies had 3 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 5 mentions for NeuroOne Medical Technologies and 2 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 1.87 beat NeuroOne Medical Technologies' score of 0.77 indicating that ENDRA Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
NeuroOne Medical Technologies Positive
ENDRA Life Sciences Very Positive

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

NeuroOne Medical Technologies currently has a consensus target price of $7.33, indicating a potential upside of 278.01%. ENDRA Life Sciences has a consensus target price of $25.00, indicating a potential upside of 459.28%. Given ENDRA Life Sciences' higher probable upside, analysts clearly believe ENDRA Life Sciences is more favorable than NeuroOne Medical Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

NeuroOne Medical Technologies has higher revenue and earnings than ENDRA Life Sciences. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroOne Medical Technologies$9.47M1.78-$3.61M-$0.95N/A
ENDRA Life SciencesN/AN/A-$7.03M-$8.15N/A

ENDRA Life Sciences has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -71.50%. NeuroOne Medical Technologies' return on equity of -115.61% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
NeuroOne Medical Technologies-71.50% -115.61% -79.63%
ENDRA Life Sciences N/A -433.64%-204.58%

Summary

NeuroOne Medical Technologies beats ENDRA Life Sciences on 11 of the 15 factors compared between the two stocks.

How does ENDRA Life Sciences compare to IRIDEX?

ENDRA Life Sciences (NASDAQ:NDRA) and IRIDEX (NASDAQ:IRIX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

ENDRA Life Sciences has a net margin of 0.00% compared to IRIDEX's net margin of -6.23%. IRIDEX's return on equity of 0.00% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ENDRA Life SciencesN/A -433.64% -204.58%
IRIDEX -6.23%N/A -11.16%

1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 20.1% of IRIDEX shares are owned by institutional investors. 10.0% of ENDRA Life Sciences shares are owned by insiders. Comparatively, 8.6% of IRIDEX shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ENDRA Life Sciences currently has a consensus price target of $25.00, suggesting a potential upside of 459.28%. IRIDEX has a consensus price target of $3.00, suggesting a potential upside of 250.47%. Given ENDRA Life Sciences' higher possible upside, research analysts clearly believe ENDRA Life Sciences is more favorable than IRIDEX.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
IRIDEX
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, ENDRA Life Sciences had 1 more articles in the media than IRIDEX. MarketBeat recorded 2 mentions for ENDRA Life Sciences and 1 mentions for IRIDEX. IRIDEX's average media sentiment score of 1.89 beat ENDRA Life Sciences' score of 1.87 indicating that IRIDEX is being referred to more favorably in the news media.

Company Overall Sentiment
ENDRA Life Sciences Very Positive
IRIDEX Very Positive

IRIDEX has higher revenue and earnings than ENDRA Life Sciences. IRIDEX is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ENDRA Life SciencesN/AN/A-$7.03M-$8.15N/A
IRIDEX$52.67M0.28-$4.44M-$0.19N/A

ENDRA Life Sciences has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market. Comparatively, IRIDEX has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Summary

IRIDEX beats ENDRA Life Sciences on 8 of the 13 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Jin Medical International?

ENDRA Life Sciences (NASDAQ:NDRA) and Jin Medical International (NASDAQ:ZJYL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Jin Medical International has higher revenue and earnings than ENDRA Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ENDRA Life SciencesN/AN/A-$7.03M-$8.15N/A
Jin Medical International$20.69M12.81$1.19MN/AN/A

Jin Medical International's return on equity of 0.00% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ENDRA Life SciencesN/A -433.64% -204.58%
Jin Medical International N/A N/A N/A

ENDRA Life Sciences currently has a consensus target price of $25.00, suggesting a potential upside of 459.28%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Jin Medical International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Jin Medical International
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

1.2% of ENDRA Life Sciences shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ENDRA Life Sciences has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market. Comparatively, Jin Medical International has a beta of 7.34, meaning that its share price is 634% more volatile than the broader market.

In the previous week, Jin Medical International had 1 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 3 mentions for Jin Medical International and 2 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 1.87 beat Jin Medical International's score of 1.12 indicating that ENDRA Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
ENDRA Life Sciences Very Positive
Jin Medical International Positive

Summary

ENDRA Life Sciences and Jin Medical International tied by winning 6 of the 12 factors compared between the two stocks.

Get ENDRA Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NDRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NDRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NDRA vs. The Competition

Export
MetricENDRA Life SciencesHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5.68M$5.95B$7.06B$13.10B
Dividend YieldN/A1.76%2.57%10.45%
P/E Ratio-0.5526.22269.0625.28
Price / SalesN/A63.22601.6191.31
Price / CashN/A33.9270.4850.90
Price / Book2.336.1012.916.24
Net Income-$7.03M$148.67M$3.45B$347.60M
7 Day Performance-2.19%1.83%1.10%1.06%
1 Month Performance-20.32%3.98%1.32%0.81%
1 Year Performance-8.02%9.21%62.43%20.90%

ENDRA Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NDRA
ENDRA Life Sciences
2.5081 of 5 stars		$4.47
flat		$25.00
+459.3%		+0.7%$5.68MN/AN/A20
LFWD
Lifeward
2.2724 of 5 stars		$7.27
+0.6%		$10.00
+37.6%		+1.4%$20.32M$22.03MN/A60
TMDIF
Titan Medical
N/A$0.14
+5.7%		N/A-60.2%$16.30M$17.63MN/A50
NMTC
NeuroOne Medical Technologies
2.5836 of 5 stars		$1.69
-0.6%		$11.67
+590.3%		-61.0%$14.80M$12.10MN/A20
IRIX
IRIDEX
2.6177 of 5 stars		$0.82
-0.6%		$3.00
+265.8%		-23.6%$14.36M$52.67MN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NDRA) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel